NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population

CompletedNA

Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd.

Conditions: Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer, Esophageal Cancer

Interventions: multi-cancer early detection

Countries: China

This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.

Eligibility overview

Sex: ALL

Age: 40 Years to 74 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* 40-74 years old
* Able to provide a written informed consent and willing to comply with all parts of the protocol procedures

Exclusion Criteria:

* With cancer-associated clinical symptoms or suspected of cancer within 30 days prior to screen
* Have definite contraindications of cancer screening examination and diagnostic procedures
* Unable to comply with the protocol procedures
* Personal history of cancer, diagnosed within the 3 years prior to expected enrollment date
* Have received or are undergoing curative cancer treatment within three years prior to recruitment. Adjuvant endocrinotherapy for cancer is not an exclusion criterion.
* Recipients of anti-tumor therapy within 30 days prior to screen
* Pregnancy or lactating women
* Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
* Recipients of blood transfusion within 7 days prior to screen
* With autoimmune diseases
* Have an acute infection or inflammation or uncontrolled chronic infection within 14 days prior to blood draw
* Unsuitable for this trial determined by the researchers (eg. hemorrhagic diseases)

Locations (4)

Fuzhou, Fujian, China
Zhengzhou, Henan, China
Nanjing, Jiangsu, China
Shanghai, Shanghai Municipality, China